SMAD2 inhibitors(Mothers against decapentaplegic homolog 2 inhibitors), TGFBR2 modulators(Transforming growth factor beta receptor 2 modulators), VEGF-A modulators(Vascular endothelial growth factor A modulators)

Therapeutic Areas

Eye Diseases

Active Indication

Choroidal Neovascularization

Inactive Indication-

Originator Organization

Hannover Medical School

Active Organization

Hannover Medical School

Inactive Organization-

Drug Highest PhasePreclinical

First Approval Date-

Regulation-

100 Clinical Results associated with miR-302d

100 Translational Medicine associated with miR-302d

100 Patents (Medical) associated with miR-302d

Literatures (Medical) associated with miR-302d

24 Apr 2024·Bioscience Reports

Expression of Concern: MiR-302e attenuates allergic inflammation in vitro model by targeting RelA

Article

01 Aug 2023·Animal BiotechnologyQ4 · AGRICULTURAL & FORESTRY SCIENCE

miR-302b promotes bovine preadipocyte differentiation and inhibits proliferation by targetingCDK2

Q4 · AGRICULTURAL & FORESTRY SCIENCE

Article

Author: Pan, Cuili ; Wang, Shuzhe ; Tang, Lin ; Ma, Yun ; Lei, Zhaoxiong ; Hu, Chunli ; Ma, Yanfen ; Wang, Pengfei ; Wei, Dawei ; Wang, Xingping

MicroRNAs have been recently reported to act as key regulators of adipogenesis, a multifactorial complex process. One miRNA, miR-302b, is an important regulator of cell proliferation and differentiation and controls cancer development, but we speculate that miR-302b may also regulate bovine adipogenesis. Herein we have evaluated the role of this miRNA in bovine adipocyte differentiation using quantitative Real-Time Polymerase Chain Reaction (qRT-PCR), Oil Red O staining, a dual-luciferase reporter. CDK2 was identified as the target gene of miR-302b, and miR-302b agomir promoted mRNA and protein expression levels of adipocyte-specific genes. In addition, a CCK-8 kit was used to show that miR-302b agomir, but not the negative control, inhibits preadipocyte proliferation. In conclusion, miR-302b promotes bovine preadipocyte differentiation and inhibits proliferation by targeting CDK2.

21 Apr 2023·International journal of molecular sciences

Human Embryonic Stem-Cell-Derived Exosomes Repress NLRP3 Inflammasome to Alleviate Pyroptosis in Nucleus Pulposus Cells by Transmitting miR-302c.

Article

Author: Yu, Yawen ; Zhang, Jiaqing ; Li, Wenting ; Xian, Tinghui ; Wu, Hao ; Tu, Mei

Recent studies have shown that the NOD-, LRR-, and pyrin domain-containing protein 3 (NLRP3) inflammasome is extensively activated in the process of intervertebral disc degeneration (IVDD), leading to the pyroptosis of nucleus pulposus cells (NPCs) and the exacerbation of the pathological development of the intervertebral disc (IVD). Exosomes derived from human embryonic stem cells (hESCs-exo) have shown great therapeutic potential in degenerative diseases. We hypothesized that hESCs-exo could alleviate IVDD by downregulating NLRP3. We measured the NLRP3 protein levels in different grades of IVDD and the effect of hESCs-exo on the H₂O₂-induced pyroptosis of NPCs. Our results indicate that the expression of NLRP3 was upregulated with the increase in IVD degeneration. hESCs-exo were able to reduce the H₂O₂-mediated pyroptosis of NPCs by downregulating the expression levels of NLRP3 inflammasome-related genes. Bioinformatics software predicted that miR-302c, an embryonic stem-cell-specific RNA, can inhibit NLRP3, thereby alleviating the pyroptosis of NPCs, and this was further verified by the overexpression of miR-302c in NPCs. In vivo experiments confirmed the above results in a rat caudal IVDD model. Our study demonstrates that hESCs-exo could inhibit excessive NPC pyroptosis by downregulating the NLRP3 inflammasome during IVDD, and miR-302c may play a key role in this process.

100 Deals associated with miR-302d

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Choroidal Neovascularization	Preclinical	DE	Hannover Medical School	28 Nov 2022

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

miR-302d

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation